{"filings":[{"id":973116,"accession_number":"0001503274-26-000028","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2026-06-10T20:16:58+00:00","items":["5.07"],"status":"ready","headline":"Quanterix shareholders reject amendment and restatement of 2017 equity incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders did not approve Proposal 4 (amend/restate 2017 Plan through June 2031); 9,677,232 for vs 24,004,124 against.","Directors William P. Donnelly and Ivana Magovčević-Liebisch elected with ~30.9M and ~30.3M votes for respectively.","Advisory vote on executive compensation passed with 27,679,636 for vs 3,881,516 against.","Ratification of KPMG as auditor for FY2026 passed with 38,728,204 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":927918,"accession_number":"0001628280-26-041773","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2026-06-09T12:06:33+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Quanterix appoints Jason Faessler as CFO effective June 22, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Faessler previously served as SVP of Finance at Bruker Corporation, leading global FP&A and Americas finance.","Employment agreement provides $475,000 base salary, $200,000 cash sign-on, and annual bonus target of 50% of base.","Equity award of 0.30% of outstanding shares in RSUs vesting in four equal annual installments.","Severance includes 12 months base salary, pro-rated target bonus, and subsidized health benefits; full vesting upon change-in-control termination.","No family relationships or material transactions with the company per Item 404(a) disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":670276,"accession_number":"0001503274-26-000024","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2026-05-26T21:25:36+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix appoints Anthony Catalano as COO; Michael Miller transitions to CTO/Products Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Catalano appointed COO effective May 14, 2026; previously SVP at Flagship Pioneering and Akoya.","Catalano receives $400k base salary, $50k sign-on bonus, and annual bonus target of 50% of salary.","Catalano awarded RSUs equal to 0.30% of outstanding shares, vesting quarterly over 4 years.","Former COO Michael Miller transitions to new role as Chief Technology and Products Officer.","Severance for Catalano: 6 months base salary (12 months with Change-in-Control), plus pro-rated bonus and COBRA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40682,"accession_number":"0001628280-26-034124","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2026-05-12T20:17:06+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Quanterix CFO Vandana Sriram to depart June 15, 2026; search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Vandana Sriram to leave effective June 15, 2026; severance includes 12 months base salary, 2026 target bonus, health benefits.","Departure not related to disagreements on accounting, financial reporting, internal controls.","Company conducting search for successor with executive search firm; CEO expresses gratitude for contributions.","Sriram remains CFO until June 15 to ensure transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93246,"accession_number":"0001503274-26-000019","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Quanterix Q1 revenue $36.4M (+20% YoY); reaffirms FY2026 guidance of $169-174M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $36.4M, up 20% YoY; GAAP gross margin 42.7%, adjusted 50.9%.","Adjusted EBITDA loss $9.8M, improved from $11.3M loss a year ago.","Cash and marketable securities $102.6M; targeting cash flow breakeven in H2 2026.","Alzheimer's diagnostics business growing; 510(k) filing with FDA expected in H2 2026.","Collaborations with Tempus AI and Life Line Screening for blood-based biomarker tests."],"consensus_eps_estimate":-0.5542,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":36415000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104705,"accession_number":"0001503274-26-000011","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix Q4 revenue $43.9M (+25% YoY); guides 2026 rev $169-174M, cash flow breakeven H2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $43.9M vs $35.2M prior year (+25%); full-year revenue $138.9M (+1% YoY).","GAAP gross margin 45.7% (Q4) and 46.8% (FY); adjusted gross margin 50.0% (Q4) and 47.3% (FY).","Adjusted EBITDA loss of $7.9M in Q4 and $44.9M for FY; cash balance $121.6M.","Initial 2026 guidance: revenue $169-174M, adjusted gross margin 49-53%, cash ~$100M year-end.","Filed 510(k) for Alzheimer's blood test; CMS set reimbursement rate of $897 for LucentAD Complete."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104704,"accession_number":"0001628280-26-001369","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","7.01","5.02","9.01"],"status":"ready","headline":"Quanterix appoints Everett Cunningham as CEO; expects to exceed FY2025 revenue and cash guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Masoud Toloue steps down effective Jan 19; receives accelerated equity vesting through Apr 30, 2026, options exercisable until Dec 31, 2026.","Everett Cunningham named President & CEO effective Jan 19; base salary $750k, sign-on cash $600k, equity grants of 1.07M time-based RSUs and 813.75K performance-based RSUs.","Performance-based RSUs vest at stock price milestones $10, $15, $20 per share over 30-day VWAP periods.","Company expects to exceed its previously issued revenue and cash guidance for FY2025 (preliminary positive)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120997,"accession_number":"0001628280-25-053420","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Quanterix appoints Hampton, Sachs to board; Donnelly named Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Garret Hampton (ex-Thermo Fisher) and Alan Sachs (ex-Thermo Fisher CMO) join board effective Nov. 20, 2025.","William Donnelly transitions from non-Executive to Executive Chair; Jeffrey Elliott named Lead Independent Director.","Paul Meister and David Walt retired from board effective same date; no disagreement cited.","Board now has nine members, seven independent; Hampton and Sachs receive standard compensation plus initial RSU grant of 0.1% of outstanding shares.","CEO Masoud Toloue to continue focusing on biomarker expansion, LucentAD Complete launch, and Akoya acquisition synergies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120996,"accession_number":"0001503274-25-000104","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix Q3 revenue $40.2M (+12.3% YoY); gross margin drops to 42.8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP gross margin 42.8% (prior year 56.3%); adjusted gross margin 45.9% (prior 50.7%).","Adjusted EBITDA loss widened to $11.9M from $5.5M loss a year ago on acquisition/restructuring costs.","Cash, equivalents, marketable securities $138.1M; expects ~$120M at year-end 2025.","Reiterates FY 2025 revenue guidance $130-135M; pro forma $165-170M including Akoya.","Captured $67M of cost synergies from Akoya; expects cash flow breakeven in 2026."],"consensus_eps_estimate":-0.5406,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":95042000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120995,"accession_number":"0001503274-25-000097","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Quanterix stockholders elect three directors, approve charter declassification and supermajority removal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Myla Lai-Goldman, Masoud Toloue, David Walt as directors for 3-year terms; broker non-votes ~4.3M.","Advisory vote to approve named executive officer compensation passed: 30.3M for, 5.5M against.","Ratified KPMG as independent registered public accounting firm for FY2025: 40.1M for.","Approved charter amendment to declassify Board of Directors: 35.7M for, 159k against.","Approved amendments to eliminate supermajority vote for charter and bylaws changes: ~35.6M for each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137600,"accession_number":"0001104659-25-092669","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Quanterix adjourns annual meeting; supermajority vote amendments need more votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting convened and adjourned without business; reconvened Sept 29, 2025 at 10am ET.","Proposals 5 & 6 to eliminate supermajority vote requirements had 99% of votes cast FOR but only 74.8% of outstanding shares (need 75%).","Board unanimously recommends voting FOR both proposals; company continues soliciting votes until Sept 28.","Stockholders who already voted need not take action; proxies will be voted at adjourned meeting unless revoked."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137593,"accession_number":"0001503274-25-000095","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K/A","filed_at":"2025-09-23T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Quanterix files pro forma financials for Akoya acquisition; combined net loss $74.6M in H1 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pro forma combined net loss for H1 2025: $74.6M ($1.61 EPS); FY2024: $101.2M ($2.21 EPS).","Total consideration ~$150M: 0.147 QTRX shares + $0.37 cash per Akoya share, plus $82.1M debt payoff.","Pro forma combined assets $464.5M, equity $333.5M as of June 30, 2025.","Akoya's long-term debt of $76.8M repaid at closing, including $5.3M prepayment penalty and exit fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137599,"accession_number":"0001503274-25-000089","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","5.03","7.01","9.01"],"status":"ready","headline":"Quanterix Q2 revenue drops 29% to $24.5M; net loss widens to $30M; guides FY25 revenue $130-135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $30.0M vs $7.4M in Q2 2024; GAAP gross margin 46.2% vs 64.7%.","Revenue $24.5M down 29% YoY; Alzheimer's Diagnostics revenue more than tripled.","Closed Akoya acquisition in early July; $64M of $85M cost reduction target achieved.","FY 2025 revenue guidance $130-135M (incl. ~2 quarters Akoya); pro forma $165-170M.","Expects cash flow breakeven in 2026; exiting 2025 with ~$120M cash."],"consensus_eps_estimate":-0.3672,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":54810000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137598,"accession_number":"0001503274-25-000083","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Quanterix reaches cooperation agreement with Kent Lake; will add independent director and seek board declassification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kent Lake withdraws its director nominations and will support the Board's candidates at the 2025 annual meeting.","Company commits to appoint new independent director by December 1, 2025 via joint executive search process.","Company will seek shareholder approval at 2025 annual meeting to declassify Board of Directors.","Kent Lake agrees to standstill and voting commitments until 30 days before nomination deadline for 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137597,"accession_number":"0001503274-25-000080","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Quanterix commits to workforce reduction targeting $18M annual savings post-Akoya integration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination plan committed July 18, 2025, to reduce operating costs and preserve cash.","Annualized cash savings expected ~$18.0 million from headcount reductions, substantially completed in Q3 2025.","Severance expenses of ~$2.5 million, all cash expenditures in 2025.","Integration plan to realize synergies from acquisition of Akoya Biosciences, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137596,"accession_number":"0001503274-25-000074","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Quanterix terminates Akoya executives post-acquisition; expects $2.8M annual savings, $3.3M severance cost","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminating certain Akoya executives under its Executive Severance Plan as part of integration.","Expects annualized cash savings of ~$2.8M from reduced costs and streamlined operations.","Anticipates ~$3.3M in severance expenses, all cash expenditures, in 2025.","Terminations part of plan to realize synergies from recently closed Akoya acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137595,"accession_number":"0001503274-25-000065","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["2.01","5.02","7.01","9.01"],"status":"ready","headline":"Quanterix completes Akoya acquisition for ~7.8M shares + $20M cash; TAM expands to $5B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Quanterix issued ~7.8M shares and paid ~$20M cash to buy Akoya, creating integrated blood & tissue biomarker platform.","Combined addressable market grows from $1B to $5B; company expects accelerated path to profitability by 2026.","CEO Masoud Toloue and CFO Vandana Sriram continue; new board members Scott Mendel and Myla Lai-Goldman appointed.","Prior directors Martin Madaus and Sarah Hlavinka resigned effective at closing; cash balance ~$163M post-transaction.","Historical financials of Akoya and pro forma financials to be filed within 71 days via 8-K/A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137594,"accession_number":"0001503274-25-000063","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.08","8.01","9.01"],"status":"ready","headline":"Quanterix sets 2025 annual meeting for Sept 23; updates proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting will be held virtually on September 23, 2025 at 9:00 a.m. ET.","Stockholder proposals for inclusion in proxy materials due by July 11, 2025.","Director nominations and other business outside Rule 14a-8 also due July 11, 2025.","Universal proxy notice for supporting non-company nominees due by July 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154971,"accession_number":"0001503274-25-000056","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Quanterix dismisses EY, hires KPMG as auditor; cites material weaknesses and restatement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EY dismissed effective after Q1 2025 10-Q filing; Audit Committee selected KPMG for FY 2025 after RFP.","EY reports on internal controls for 2023 and 2024 contained adverse opinions due to material weaknesses.","Material weaknesses cited: inventory valuation (including labor/overhead capitalization) and Accelerator Laboratory revenue controls.","Company restated financials for periods from Q1 2022 through Q2 2024 due to inventory valuation error.","No disagreements with EY on accounting principles; new auditor KPMG has had no pre-engagement consultations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154970,"accession_number":"0001503274-25-000051","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Quanterix Q1 revenue down 5% to $30.3M, net loss widens; approves $30M annual cost cuts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $30.3M (-5% YoY); GAAP net loss $20.5M vs $11.2M prior year.","Adjusted gross margin 49.7% vs 51.2%; cash $269.5M with adjusted cash burn $9.0M.","Board approved cost reduction: $15M savings in 2025, annualized $30M; ~$9M from headcount with $1.5M severance.","2025 standalone revenue guidance $120-130M (down 5-13% YoY); GAAP gross margin 55-59%; adjusted cash burn $35-45M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":30333000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154969,"accession_number":"0001104659-25-040749","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Quanterix and Akoya amend merger consideration; each Akoya share gets 0.1461 QTRX shares + $0.38 cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Per Akoya share, stockholders receive 0.1461 Quanterix shares plus $0.38 cash; aggregate cash capped at $20M.","Akoya may draw up to $30M in convertible notes from Quanterix between June 15 and deal closing or termination.","Quanterix will not hold a stockholder meeting; Akoya stockholders representing ~55.6% have agreed to vote in favor.","Akoya board will nominate two members to Quanterix board, replacing two existing directors at closing.","Akoya pays $2.6M termination fee in defined circumstances; deal must close by August 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154968,"accession_number":"0001503274-25-000042","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Quanterix agrees to provide Akoya up to $30M in convertible notes pending merger close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Convertible notes up to $30M aggregate principal; draw period runs May 15, 2025 to July 9, 2025 (or Jan 9, 2026 if merger extended).","Interest at SOFR plus applicable margin; monthly interest payable in cash, subordinated to Akoya's existing MidCap debt.","Notes convertible into Akoya common stock at a conversion price based on merger exchange ratio and Quanterix 10-day VWAP.","Conversion capped at 19.99% of Akoya common stock unless stockholder approval obtained; no conversion before merger termination.","Proceeds intended to repay Akoya's existing indebtedness and provide working capital pending merger close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173484,"accession_number":"0001503274-25-000038","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix appoints William Donnelly Chairman; Director Madaus resigns after majority vote loss","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William P. Donnelly appointed Chairman of the Board effective March 24, 2025.","Martin D. Madaus resigns from Board and committees no later than the 2025 annual meeting.","Resignation follows Madaus receiving less than a majority of votes cast for reelection at the 2024 annual meeting.","Madaus's resignation is not due to any disagreement with the company on operations, policies, or practices.","Board deferred the resignation until after discussions with Akoya Biosciences concluded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173483,"accession_number":"0001503274-25-000029","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix Q4 2024 revenue $35.2M (+11% YoY); FY 2025 guidance $140-146M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $35.2M, up 11% YoY; net loss $11.6M vs $8.8M prior year.","Full-year 2024 revenue $137.4M (+12%); net loss $38.5M improved $10.2M.","Ended 2024 with $291.7M cash; 2025 cash usage guided at $55-65M (incl. $20M EMISSION payment).","FY 2025 revenue outlook $140-146M (2-6% growth) excluding Lucent Diagnostics and Akoya impact.","Simoa ONE instrument launch planned by end-2025; FDA breakthrough designation for LucentAD Complete."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173482,"accession_number":"0001503274-25-000022","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Quanterix highlights Akoya acquisition benefits; responds to Kent Lake director nominations","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition unlocks $5B addressable market in spatial biology and $10B Alzheimer's diagnostics opportunity.","Expects ~$40M annual run-rate cost synergies by end of 2026, with $20M in the first year after close.","Targets ~$1B revenue and ~15% EBIT margins within five years post-close; positive free cash flow expected in 2026.","Kent Lake PR LLC nominated three director candidates for 2025 Annual Meeting; Quanterix criticizes assumptions as flawed.","Transaction expected to close in Q2 2025, pending shareholder approvals and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173481,"accession_number":"0001503274-25-000017","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quanterix and Akoya merger receives HSR clearance; waiting period expired Feb 24","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Hart-Scott-Rodino waiting period expired at 11:59 p.m. ET on February 24, 2025.","Merger remains subject to adoption by Akoya stockholders and Quanterix stockholder approval.","Quanterix expects the transaction to close in Q2 2025.","Merger announced January 9, 2025; Akoya to become wholly owned subsidiary of Quanterix."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173480,"accession_number":"0001503274-25-000010","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix adopts 2025 AIP with CEO target of $675K and CFO target of $325.5K","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Compensation Committee approved 2025 annual cash incentive plan on January 27, 2025.","Awards based on achievement of corporate and personal performance objectives.","CEO Masoud Toloue target award: $675,000 (percentage of base salary).","CFO Vandana Sriram target award: $325,500; actual payout may vary per committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173479,"accession_number":"0001503274-25-000006","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix reports preliminary Q4 revenue $34.9M, FY 2024 revenue $137.2M, up 12% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue ~$34.9M, +11% YoY; Accelerator up 22% to $8.6M, Instruments down 6% to $3.1M.","FY 2024 revenue ~$137.2M, +12% YoY; Consumables up 8% to $69.3M, Accelerator up 36% to $38.0M.","Instruments fell 33% to $10.5M in FY; cash and equivalents ~$292M at year end; used ~$32M in cash.","Earnings call for Q4/FY 2024 results scheduled for March 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":137421000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173478,"accession_number":"0001503274-25-000004","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Quanterix to acquire Akoya Biosciences; expands addressable market to $5B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction expected to close in Q2 2025; combined cash at close ~$175M.","Combined installed base of 2,300+ instruments; addressable market grows from $1B to $5B.","Expands Quanterix from neurology into oncology and immunology via Akoya's tissue biomarker platform.","Post-closing, combined company will operate under Quanterix name; integration team being formed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173477,"accession_number":"0001503274-25-000002","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Quanterix to acquire Akoya Biosciences in stock deal; exchange ratio 0.318","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Akoya shareholders to receive 0.318 Quanterix shares per share; no cash consideration except for fractional shares.","Voting agreements from ~55.9% of Akoya stock and ~6.2% of Quanterix stock; lock-up agreements cover ~35.7% of QTRX shares for 90 days.","Termination fees: $7M from Akoya, $9M from Quanterix; Quanterix may provide $30M bridge convertible notes after March 15, 2025.","Expected close by July 9, 2025 (extendable to Jan 9, 2026); Akoya to nominate two directors to Quanterix board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173476,"accession_number":"0001503274-25-000001","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Quanterix completes acquisition of Emission Inc. for up to $70M total","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $10M; additional $10M payable upon technical milestones.","Up to $50M in earnout payments through Dec 31, 2029, contingent on performance milestones.","Earnout expected to be funded from cash generated by achievement of earnout criteria.","No financial statements or pro forma info required for this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190467,"accession_number":"0001503274-24-000022","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Quanterix acquires EMISSION for $10M upfront, up to $70M total, expanding bead technology","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $10M cash; additional $10M on technical milestones; up to $50M earnout through 2029 based on performance.","Transaction expected to close in January 2025; no regulatory approval required.","EMISSION manufactures proprietary dye-encapsulating magnetic beads for multi-plex assays; will integrate with Quanterix's next-gen Simoa platform.","Deal expected to be accretive to revenue and gross margins in 2026.","Shareholders can repurchase Emission for $10M after 5 years if annual revenues <$5M; Quanterix retains perpetual IP license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190466,"accession_number":"0001503274-24-000020","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Quanterix receives Nasdaq delinquency notice for delayed Q3 10-Q filing due to restatement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Nov 21; Company has until Jan 20, 2025 to submit compliance plan; may get extension to May 13, 2025.","Delay stems from restatement of audited FY 2022 and 2023, and unaudited quarterly periods from Q1 2022 through Q2 2024.","Company expects to file restated financials and the Form 10-Q by end of 2024.","Nasdaq listing and trading unaffected immediately, but non-compliance may lead to delisting if not resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190465,"accession_number":"0001503274-24-000014","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"Quanterix restates prior financials for inventory errors; Q3 revenue $35.7M (+13% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.7M (+13% YoY); GAAP gross margin 58.9%; reaffirms FY2024 revenue guidance $134-138M.","Restating financials for 2021-2024 due to inventory capitalization errors; non-reliance on prior statements.","Estimated restatement impacts: 2023 gross profit +$2.1M, operating loss -$2.3M; no material impact on cash or revenue.","Material weaknesses in internal control over inventory valuation continue; remediation ongoing.","Launched LucentAD Complete multi-marker Alzheimer's test; Mt. Sinai deploying blood-based biomarkers using Quanterix assays."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":102260000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190463,"accession_number":"0001628280-24-042263","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K/A","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix appoints Jeffrey T. Elliott to Nominating and Governance Committee","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jeffrey T. Elliott appointed to Nominating and Governance Committee effective October 2, 2024.","Elliott joined Quanterix board on August 19, 2024, as reported in original 8-K.","Amendment solely adds committee assignment; no other changes to prior disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190464,"accession_number":"0001628280-24-042118","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix appoints Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Magovčević-Liebisch appointed effective Oct 2, 2024 as Class III director with term expiring at 2026 annual meeting.","Received initial equity award valued at $400,000 (60% stock options, 40% RSUs) vesting over three years.","She serves as President and CEO of Vigil Neuroscience, with over 25 years biopharma experience.","Appointed to the Compensation Committee of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206963,"accession_number":"0001628280-24-038023","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Jeffrey Elliott appointed to Quanterix board; brings Exact Sciences experience","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed effective August 19, 2024 as a Class I director with term expiring at 2027 annual meeting.","Mr. Elliott served as CFO of Exact Sciences (2016-2024) and COO (2021-2023), scaling operations and overseeing acquisitions.","Received initial equity award valued at $400,000: 60% stock options and 40% RSUs, vesting over three years.","CEO Masoud Toloue cited Elliott's experience in scaling Alzheimer's disease testing infrastructure as valuable.","No family relationships or material transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206962,"accession_number":"0001503274-24-000006","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix Q2 revenue up 11% to $34.4M; net loss widens to $9.5M; cuts FY2024 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $34.4M (+10.8% YoY); GAAP gross margin 58.3% vs 61.7% prior year.","Net loss $9.5M, up $3.4M from prior year; cash usage $5.1M in quarter.","Revised FY2024 revenue guidance to $134M-$138M from $139M-$144M due to constrained capital environment.","Cash usage for 2024 now expected at higher end of $25M-$30M range.","New Alzheimer's diagnostic partnerships with Mt. Sinai, Banner Health, UCSF, and KingMed Diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":66447000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224257,"accession_number":"0001104659-24-069615","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Quanterix stockholders elect directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Karen A. Flynn and Martin D. Madaus elected as independent directors for three-year terms.","Say-on-pay approved: 25,850,081 for, 530,291 against, 106,358 abstain.","Ratification of Ernst & Young as independent auditor for FY2024 approved: 31,337,320 for, 152,095 against.","Broker non-votes of 5,106,768 on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224256,"accession_number":"0001104659-24-065578","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix appoints Michael Miller as COO; prior COO Daniel Pikora resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Miller, age 60, appointed COO effective May 21, 2024, succeeding Daniel Pikora who resigned.","Miller previously served as SVP, Accelerator and Clinical Services at Quanterix since July 2021.","Miller's base salary is $400,000; eligible for annual bonus up to 50% of base salary at target.","Received initial equity grant of $1.0M (70% options, 30% RSUs) vesting 25% on May 21, 2025 with remainder monthly.","Pikora will remain for a limited transition period and is pursuing other opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224255,"accession_number":"0001558370-24-007059","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Quanterix Q1 revenue $32.1M (+12.7%); net loss $10.1M; FDA breakthrough for P-tau217 test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $32.1M (+12.7% YoY); net loss $10.1M (increase of $4.0M YoY).","GAAP gross margin 61.2% (up 170 bps); non-GAAP gross margin 54.5% (up 140 bps).","FY 2024 guidance unchanged: revenue $139-$144M, GAAP gross margin 57-61%, non-GAAP 51-55%.","Director Brian J. Blaser resigned board eff. May 3, 2024 to become CEO of QuidelOrtho; no disagreement.","Simoa P-tau217 blood test granted FDA Breakthrough Device; Lilly launched CertuitAD test on SP-X platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":32066000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224254,"accession_number":"0001104659-24-046830","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix enhances CEO & CFO severance benefits; director Olson not seeking re-election","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Laurie Olson will not stand for re-election at June 3, 2024 Annual Meeting; no disagreement with company.","CEO Toloue's severance: salary continuation extended to 24 months (from 12) on change-in-control termination.","CFO Sriram's severance: salary continuation & COBRA increased to 12 months (from 6); bonus becomes full target (vs pro-rated) on change-in-control termination.","Both amendments effective April 9-11, 2024; apply if terminated without cause or resign for good reason near change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243596,"accession_number":"0001558370-24-002184","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix Q4 revenue up 22% to $31.5M, net loss narrows; guides FY2024 revenue $139-144M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $31.5M (+22% YoY); GAAP gross margin 53.2% (up from 48.8%); net loss $12.4M vs $18.6M.","Full-year 2023 revenue $122.4M (+16%); GAAP gross margin 57.7% vs 44.4%; net loss $32.3M vs $96.7M.","Completed corporate transformation; new assays in production. Collaborations with Mayo Clinic, Mass General Brigham, others for Alzheimer's diagnosis.","2024 guidance: revenue $139-144M (research-only), GAAP gross margin 57-61%, non-GAAP 51-55%, cash usage $25-30M.","Eli Lilly launched pTau217 blood-based diagnostic test on Quanterix platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":122368000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243595,"accession_number":"0001558370-24-001746","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix reschedules Q4/FY 2023 earnings call to Feb 29; reaffirms guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Earnings call moved from Feb 26 to Feb 29, 2024 to align with 10-K filing deadline.","Company reaffirms 2023 revenue, gross margin, and cash usage in line with prior guidance (Jan 10, 2024).","No specific financial numbers provided; full results to be released on Feb 29 prior to call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243594,"accession_number":"0001104659-24-008231","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix sets 2024 bonus targets and amends CEO/CFO severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Masoud Toloue target award $650,000; CFO Vandana Sriram target $312,312 under 2024 AIP.","CEO employment amended: 24-month salary continuation if terminated without cause or for good reason near change-in-control.","CFO employment amended: 12-month salary continuation under same change-in-control termination conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243593,"accession_number":"0001558370-24-000191","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix reports preliminary FY2023: double-digit revenue growth, non-GAAP GM ~50%, >$300M net cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2023 double-digit revenue growth; GAAP gross margin in high 50's, non-GAAP ~50% (improvement of 1200 bps).","Net cash >$300M; annual cash burn reduced by >3x.","Over 950 instruments installed; lab services capability >0.75M tests/year (up 50%); manufacturing capacity >4M tests/year (up 300%).","Innovation rate >20 assays per year; development time reduced from >18 months to <6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":122368000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261008,"accession_number":"0001558370-23-017788","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix Q3 revenue $31.3M (+18% YoY), net loss narrows; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $31.3M (+18% YoY); GAAP net loss narrowed to $7.8M from $35.1M.","GAAP gross margin improved to 56.8% (41.1% prior year); non-GAAP gross margin 48.6% (34.9%).","FY 2023 revenue guidance raised to $118-120M from $110-116M; cash usage outlook lowered to $20-25M.","Launched LucentAD p-Tau 217 blood-based Alzheimer's test; Simoa platform used in Eli Lilly's p-Tau 217 validation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":90819000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278276,"accession_number":"0001104659-23-094228","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix appoints William P. Donnelly to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donnelly, former EVP and CFO of Mettler-Toledo, appointed effective August 17, 2023.","He will serve as Class III director until 2026 annual meeting and join Audit Committee.","Initial equity award valued at $400,000 (60% stock options, 40% RSUs) with three-year vesting.","Annual retainer of $40,000 for Board service plus $10,000 for Audit Committee, pro-rated.","Company cites his experience as valuable for scaling Alzheimer's blood biomarker strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278275,"accession_number":"0001104659-23-089128","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quanterix appoints Vandana Sriram CFO effective Aug 21; Doyle retires Mar 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vandana Sriram becomes CFO on August 21, 2023, replacing Michael Doyle who moves to Executive Director, Finance until retirement.","Sriram's base salary set at $440,000; eligible for annual bonus target of 70% of base.","Sign-on equity award of $800,000 (70% stock options, 30% RSUs) vesting over four years.","Eligible for annual equity award of up to $1.5M in next long-term cycle starting 2024.","Doyle to retire on March 31, 2024; will serve as Executive Director, Finance until then."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278274,"accession_number":"0001558370-23-013642","cik":1503274,"company_name":"Quanterix Corp","ticker":"QTRX","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quanterix Q2 revenue $31M (+32% YoY), net loss narrows to $6.1M; raises FY revenue guidance to $110-116M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $31.0M, +32% YoY, including $1.5M one-time product/license benefit; 9% sequential growth.","GAAP gross margin 61.7% vs 37.1%; non-GAAP gross margin 56.4% vs 29.1%.","Net loss $6.1M vs $24.9M prior year; near break-even cash flow; cash $329.5M.","Launched LucentAD blood test for Alzheimer's; positive Bio-Hermes study correlation with amyloid PET.","FY 2023 revenue outlook raised to $110-116M; cash burn lowered to $30-35M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":59485000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":137784995.91509435,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-07T23:59:59+00:00|278274"}